

Manufacturer	NDC 11	Drug Name	Commercial Launch Date
60505627001	Cetrorelix Acetate for injection .25mg / vial	5/13/2024	200.72

Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally

No marketing activities were conducted. We are priced below the brand and in line with 3 of our generic competitors, both of which are just below the brand.

The estimated volume of patients who may be prescribed the drug

9430

Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval

N

Date and price of acquisition if the drug was not developed by the manufacturer

--